Key result
Mitochondrial cardiomyopathy involves complex genetic variants with emerging precision therapies like gene therapy under investigation.
Provides a comprehensive overview of the genetic complexities, diagnostic advancements, and emerging precision medicine strategies for mitochondrial cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May guide precision diagnostics and therapies in mitochondrial cardiomyopathy; leaves open prospective validation before practice change.
Genetic cardiomyopathies caused by pathogenic variants in nuclear DNA (nDNA) that encodes contractile sarcomere proteins are among the best understood of all the cardiomyopathies. By contrast, mitochondrial cardiomyopathy is caused by a dysfunction in mitochondrial oxidative phosphorylation due to pathogenic variants in either nDNA or the maternal mitochondrial DNA (mtDNA). Unlike contractile protein defects, which generally follow predictable Mendelian inheritance patterns, mitochondrial cardiomyopathy is genetically complex as a result of the distinctive characteristics of the mitochondrial genome, which influence patterns of maternal inheritance, heteroplasmy and tissue-specific variations in mtDNA variant load. Both single-gene nDNA and mtDNA variants can impair cardiac energetics, resulting in a wide clinical spectrum ranging from severe, childhood-onset to milder, adult-onset cardiomyopathy. Furthermore, the intricate metabolic demands of the heart mean that mitochondrial dysfunction can be influenced by a broad array of genetic and environmental modifiers. A greater recognition of these complexities and the integration of genomic sequencing, novel biomarkers and functional imaging have advanced diagnostic and therapeutic approaches. Emerging treatment strategies, such as metabolic supplementation, gene therapy and genome editing, are under investigation. In this Review, we synthesize the molecular and clinical landscape of mitochondrial cardiomyopathy, highlighting the ongoing challenges and prospects of precision medicine in this rapidly evolving field.
No takes yet. Share an insight, caveat, or question.
Imai‐Okazaki et al. (2026) conducted a review in Mitochondrial cardiomyopathy. Mitochondrial cardiomyopathy presents a complex genetic and clinical landscape driven by nDNA and mtDNA variants, with emerging precision medicine strategies like gene therapy under investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: